Potential impact of nirsevimab and bivalent maternal vaccine against RSV bronchiolitis in infants: A population-based modelling study

• Үндсэн зохиолчид: Mónica López-Lacort (Зохиогч), Ana Corberán-Vallet (Зохиогч), Francisco J. Santonja (Зохиогч), Cintia Muñoz-Quiles (Зохиогч), Javier Díez-Domingo (Зохиогч), Alejandro Orrico-Sánchez (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Elsevier, 2024-08-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Background: A new monoclonal antibody (nirsevimab; Beyfortus®) and a bivalent prefusion RSV vaccine (Abrysvo®) for maternal immunization have been approved recently. This is a modelling study to estimate the potential impact of different immunization programs with these products on RSV-bronchiolitis...